Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 2, 2012

View Archived Issues

New claudin-6-binding antibodies patented in Germany

Novel platinum(IV) complexes disclosed by Universidad Autonoma de Madrid

Allergan presents novel agents for ocular disorders

Galderma Pharma prepares new agent for rosacea

New human papillomavirus vaccines developed in China

Novel orexin OX receptor antagonists discovered at Actelion Pharmaceuticals

New mechanism of action reveals potential of salirasib to treat rare lung disorder

Two-gene signature predicts prognosis of previously untreated chronic lymphocytic leukemia

Shire and Sangamo BioSciences enter agreement for hemophilia therapeutics

IDRI contributes to Sabin Vaccine Institute's first-ever hookworm vaccine study

Boehringer Ingelheim selects Nanobody candidate from Ablynx alliance

ThromboGenics plans to resubmit ocriplasmin BLA for priority review

Study identifies new therapeutic target for refractory inflammation in COPD

Impax Pharmaceuticals gains U.S. rights to migraine therapy

FDA advisory committee sets review date for lorcaserin NDA resubmission

U.S. team designs new nanoparticle delivery systems to target chemotherapy to cancer cells

Phase III tuberculosis trial completes enrollment

Eusa Pharma acquires Asparec rights

Phase III lubiprostone study meets primary endpoint

New gene expression signature predicts outcome of patients with basal-like breast cancer

Boston Scientific launches Promus Element Plus stent system in Europe

Navidea Biopharmaceuticals receives CHMP advice on Lymphoseek MAA

Dosing begins in phase II AFN-1252 study in ABSSSI

WHO releases roadmap for work to eliminate neglected tropical diseases

Athersys receives grant to develop stem cell therapy for traumatic brain injury

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 12, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 12, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...